📰 Curated Industry Article
This is a summary of a full article from a trusted healthcare and insurance publication. Click “Read Full Article” below to read the complete story.
Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for Lisraya as a treatment for the rare inflammatory disorder dermatomyositis. Licensed from Pfizer, this once-daily pill designed to block JAK1 and TYK2 proteins is also in clinical development for three additional rare immunological disorders, each with blockbuster potential.
The post FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant’s Biz Strategy appeared first on MedCity News.
💡 What This Means For You
[armfox_dynamic_insight]
ARMFOX HEALTHCARE
Stay Informed. Protect Your Future.
No pressure. No jargon. Just honest answers from advisors who genuinely care about your family’s protection.
📰 This article is sourced from a trusted healthcare and insurance industry publication. Armfox Healthcare shares this for informational purposes only. Always consult a licensed advisor for personalized guidance.